ImageneBio, Inc. (NASDAQ:IMA – Get Free Report) saw a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 49,297 shares, a decline of 87.2% from the July 30th total of 384,525 shares. Approximately 0.4% of the company’s shares are sold short. Based on an average daily volume of 9,956 shares, the short-interest ratio is presently 5.0 days.
Institutional Investors Weigh In On ImageneBio
Hedge funds have recently bought and sold shares of the business. Barclays PLC increased its stake in shares of ImageneBio by 170.8% during the fourth quarter. Barclays PLC now owns 10,797 shares of the company’s stock valued at $74,000 after purchasing an additional 6,810 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of ImageneBio in the 4th quarter worth approximately $76,000. Millennium Management LLC purchased a new stake in shares of ImageneBio in the 4th quarter worth approximately $79,000. T3 Companies LLC bought a new position in ImageneBio during the 4th quarter valued at approximately $91,000. Finally, Jane Street Group LLC bought a new position in ImageneBio during the 4th quarter valued at approximately $103,000. Institutional investors own 75.00% of the company’s stock.
Wall Street Analyst Weigh In
IMA has been the topic of a number of recent analyst reports. Wedbush reiterated an “underperform” rating on shares of ImageneBio in a research report on Monday, May 11th. HC Wainwright assumed coverage on shares of ImageneBio in a report on Friday, August 21st. They issued a “buy” rating and a $28.00 price target on the stock. Wall Street Zen downgraded shares of ImageneBio from a “sell” rating to a “strong sell” rating in a research report on Sunday, May 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $29.00.
ImageneBio Trading Down 1.8%
Shares of IMA stock traded down $0.10 during midday trading on Thursday, reaching $5.33. 17,436 shares of the stock were exchanged, compared to its average volume of 147,437. ImageneBio has a 1 year low of $3.94 and a 1 year high of $13.98. The firm has a market cap of $60.50 million, a PE ratio of -1.16 and a beta of 0.76. The company’s 50 day moving average is $5.79 and its two-hundred day moving average is $5.82.
ImageneBio (NASDAQ:IMA – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.27. As a group, equities analysts expect that ImageneBio will post -3.23 EPS for the current fiscal year.
About ImageneBio
ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.
See Also
- Five stocks we like better than ImageneBio
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for ImageneBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImageneBio and related companies with MarketBeat.com's FREE daily email newsletter.
